GlassScriptPhysician profile
Aurelio A Ortiz
NPI 1811958945
$14,310.57
in general payments reported to CMS, 2019-2025
29 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,653 · 2021: $2,763 · 2022: $2,953 · 2023: $2,017 · 2024: $2,068 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401 · Education: $24.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.44 |
| Education | $24.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,471.29 | 2019-2025 | Jot Dx, Aveir, Gallant |
| Medtronic, INC. | $1,576.03 | 2021-2025 | Onyx Frontier, Cobalt Dr Mri Surescan, Symplicity G3 |
| Medtronic Vascular, INC. | $1,174.45 | 2019-2020 | |
| Amgen INC. | $1,155.32 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $1,054.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $809.25 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $774.37 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $769.26 | 2019-2025 | |
| Boston Scientific Corporation | $598.00 | 2021-2025 | Watchman Flx, General - Therapies |
| Pfizer INC. | $456.72 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $441.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $424.02 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $411.44 | 2024-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $154.57 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $122.19 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.14 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $105.47 | 2022-2023 | Mounjaro |
| Impulse Dynamics (USA) INC. | $102.87 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $84.24 | 2019 | |
| Cardiovascular Systems INC. | $79.19 | 2021 | |
| Antares Pharma, INC. | $75.88 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Cvrx, INC. | $67.20 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $66.90 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $52.08 | 2025 | Assure Wcd |
| Halozyme INC | $46.74 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $40.14 | 2023 | Inpefa |
| Heartflow, INC. | $31.49 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $24.10 | 2023 | Arcalyst |
| Vivaquant INC, Dba Rhythm Express | $20.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurelio Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.